A cross-sectional observational study to establish the association between ECOG performance status and age and administration of doublet or triplet chemotherapy containing Xeloda® (capecitabine) in advanced gastric cancer patients. European Journal of Oncology and Environmental Health, [S. l.], v. 18, n. 4, p. 173–180, 2014. Disponível em: https://mattioli1885journals.com/index.php/EJOEH/article/view/2443.. Acesso em: 18 jul. 2024.